表紙:次世代シーケンシング(NGS)データ解析の世界市場
市場調査レポート
商品コード
994710

次世代シーケンシング(NGS)データ解析の世界市場

Next Generation Sequencing (NGS) Data Analysis

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 273 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.11円

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

次世代シーケンシング(NGS)データ解析の世界市場
出版日: 2022年01月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 273 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の次世代シーケンシング(NGS)データ解析の市場規模は、分析期間(2020年~2027年)に12.2%のCAGRで成長する見通しで、2020年の6億3,880万米ドルから、2027年には14億米ドルに達すると予測されています。

当レポートで分析されているセグメントの1つであるサービスは、分析期間中に12.5%のCAGRで成長し、8億3,620万米ドルに達すると予測されています。

当レポートは、世界の次世代シーケンシング(NGS)データ解析市場について調査しており、Covid-19の影響、動向や成長要因、地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

調査対象企業の例

  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Congenica Ltd.
  • DNAnexus Inc.
  • Dnastar, Inc.
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd.
  • Fabric Genomics, Inc.
  • Genuity Science
  • Golden Helix, Inc.
  • Illumina, Inc.
  • Intrexon Bioinformatics Germany GmbH
  • Pacific Biosciences of California, Inc.
  • Partek Incorporated
  • PierianDx
  • Qiagen
  • SciGenom Labs Pvt. Ltd.
  • Thermo Fisher Scientific, Inc.

目次

I. 調査手法

II. エグゼクティブサマリー

  • 市場概要
    • インフルエンサー市場の洞察
    • 世界市場の軌跡
    • Covid-19の影響と迫り来る世界の景気後退
  • 主要企業
  • 動向と推進要因
  • 世界市場の見通し

III. 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

IV. 競合

  • 企業プロファイル:33社
目次
Product Code: MCP22378

Global Next Generation Sequencing (NGS) Data Analysis Market to Reach US$1.2 Billion by the Year 2026

Next-generation sequencing (NGS) data analysis is widely used for investigating genomic and epigenomic patterns related to a wide range of biological processes. NGS data analysis encompasses primary, secondary and tertiary analysis steps, with some of these stages holding potential for automation through new sequencing solutions. Growth in the global market is set to be driven due to extensive uptake of the technology for analysis of RNA and DNA sequences. Cloud-based platforms are rapidly emerging as favorable solutions for performing computationally intensive activities during NGS data analysis makes it fast and simple for researchers to acquire computational resources for conducting large-scale data analysis of NGS. Recent technological advancements in cloud computing and bioinformatics have led to the development of a wide array of cloud-based bioinformatics platforms and services for carrying out large-scale NGS data analysis, which is likely to propel significant market growth in the coming years. NGS methods are being extensively employed in genomic research, clinical diagnosis, and for oncology precision medicine, particularly for the diagnosis of breast and lung cancers. The rising prevalence of cancer cases across the globe is expected to boost growth in the global NGS data analysis market in the near future. Moreover, with tangible progress made towards personalized treatment of diseases, there is an increased demand for rapid and precise sequencing interpretation algorithms and tools that can help in expediting data analysis.

Amid the COVID-19 crisis, the global market for Next Generation Sequencing (NGS) Data Analysis estimated at US$549.2 Million in the year 2020, is projected to reach a revised size of US$1.2 Billion by 2026, growing at a CAGR of 14.1% over the analysis period. Services, one of the segments analyzed in the report, is projected to grow at a 14.9% CAGR to reach US$814.1 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the NGS Commercial Software segment is readjusted to a revised 13% CAGR for the next 7-year period. This segment currently accounts for a 44% share of the global Next Generation Sequencing (NGS) Data Analysis market. Analytical software is expected to exhibit robust growth over the next few years, attributed to the increased awareness and growing demand for sequencing technologies. The vast quantities of data generated via NGS require management platforms and solutions, which is resulting in the rising demand for such algorithms and tools. Companies lacking the necessary infrastructure for data analysis, interpretation, and management are increasingly adopting cost-effective NGS data analysis services.

The U.S. Market is Estimated at $238.7 Million in 2021, While China is Forecast to Reach $128.6 Million by 2026

The Next Generation Sequencing (NGS) Data Analysis market in the U.S. is estimated at US$238.7 Million in the year 2021. The country currently accounts for a 37.6% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$128.6 Million in the year 2026 trailing a CAGR of 15.1% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.8% and 13.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.1% CAGR while Rest of European market (as defined in the study) will reach US$101.9 Million by the end of the analysis period. The US is a major regional market for NGS data analysis, attributed to the presence of several established players, growing demand for personalized medicine, and launch of several large-scale genome sequencing projects in the region. Europe represents another major market. The region`s dominance is attributed to the presence of several key global players, including Agilent Technologies, Illumina, and Thermo Fisher Scientific, coupled with the presence of a large number of regional players engaged in developing NGS data analysis software. There are also various European universities that are involved in conducting various NGS research projects, which is driving the adoption of NGS software tools in the region.

Select Competitors (Total 111 Featured) -

  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Congenica Ltd.
  • DNAnexus Inc.
  • Dnastar, Inc.
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd.
  • Fabric Genomics, Inc.
  • Genuity Science
  • Golden Helix, Inc.
  • Illumina, Inc.
  • Intrexon Bioinformatics Germany GmbH
  • Pacific Biosciences of California, Inc.
  • Partek Incorporated
  • PierianDx
  • Qiagen
  • SciGenom Labs Pvt. Ltd.
  • Sophia Genetics
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • NGS Data Analysis: Unraveling Critical Clues to Solve Scientific Problems
    • NGS Data Analysis: Insights into File Formats & Downstream Analysis
    • File Formats for NGS Raw Data
    • NGS Data: Downstream Analysis
    • Impact of Covid-19 and a Looming Global Recession
    • 2020 Marked as a Year of Disruption & Transformation
    • The Never-Ending "Race" Between the Virus & Vaccines Continues. Amidst this Chaotic Battle, Where is the World Economy Heading Now & Beyond?
    • Omicron Spreads Panic Worldwide; Omicron Variant Brings Back Memories & Fears of the Worst Part of the 2020 Pandemic
    • EXHIBIT 1: Time is of Essence! What We Know So Far - "Vaccine Efficiency against New Strains is Decreasing"
    • Short-term Impact of Omicron on Travel
    • Financial Impact
    • Scientists Seek to Gather More Information on Omicron
    • Pharma Firms Aim to Improve Existing Vaccines to Counter Omicron
    • Omicron: Impact on Travel Industry
    • Steps taken by the Countries to Prevent Transmission of Omicron Variant
    • With IMF Making an Upward Revision of Global GDP for 2021, Companies Are Bullish About an Economic Comeback Despite a Continuing Pandemic
    • EXHIBIT 2: A Strong Yet Exceedingly Patchy & Uncertain Recovery Shaped by New Variants Comes Into Play: World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
    • Impact of COVID-19 on Next Generation Sequencing (NGS) Data Analysis
    • Great Promise of NGS in Fight against COVID-19 Brings Spotlight on NGS Data Analysis Market
    • Global Market Overview and Prospects
    • Next-Generation Sequencing (NGS) Data Analysis Market Witnesses Burgeoning Growth
    • Key Market Drivers and Inhibitors
    • Market Analysis
    • US and Europe Lead, Asia-Pacific to Witness Growth
    • Analysis by Product
    • Analysis by Workflow
    • Analysis by Mode
    • Analysis by Read Length
    • Analysis by End-Use
    • Competitive Landscape
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Next Generation Sequencing Market Drives the Demand for NGS Data Analysis
    • Increasing R&D Activities in NGS
    • Rising Use of NGS in Drug Discovery Drives Growth of NGS Data Analysis
    • Rising Application of Whole Genome Sequencing Drives Demand for Faster Secondary Analysis Tools
    • Technological Advancements in Sequencing Techniques and Data Integration
    • Research Initiatives for the Development of NGS-based In-vitro Diagnostics
    • The Need for Large-scale NGS Data Analysis Pushes for Cloud-enabled Bioinformatics Services
    • NGS Data Analysis Using Big Data Gains Ground
    • Improving Regulatory & Reimbursement Scenario for NGS-based Diagnostic Tests
    • Increase in Genome Mapping Programs
    • Declining Costs of Genome Sequencing Drive Market Growth
    • Growth of Long-Read Sequencing to Propel the Market for NGS Data Analysis
    • Aging Demographics Present Opportunities
    • EXHIBIT 3: Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030
    • EXHIBIT 4: Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    • Growing Prevalence of Chronic Diseases to Boost the Market Prospects
    • EXHIBIT 5: Rising Diabetes Prevalence: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045
    • EXHIBIT 6: Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    • EXHIBIT 7: Breakdown of Total Number of Cancer Cases by Region: 2020
    • EXHIBIT 8: Breakdown of Total Number of Cancer Cases by Type: 2020
    • Market Challenges
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2021 & 2027
    • TABLE 3: World Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 4: World 7-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
    • TABLE 5: World Current & Future Analysis for Ngs Commercial Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 6: World 7-Year Perspective for Ngs Commercial Software by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
    • TABLE 7: World Current & Future Analysis for Tertiary Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World 7-Year Perspective for Tertiary Data Analysis by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
    • TABLE 9: World Current & Future Analysis for Primary Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 10: World 7-Year Perspective for Primary Data Analysis by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
    • TABLE 11: World Current & Future Analysis for Secondary Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 12: World 7-Year Perspective for Secondary Data Analysis by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
    • TABLE 13: World Current & Future Analysis for In-House by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World 7-Year Perspective for In-House by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
    • TABLE 15: World Current & Future Analysis for Outsourced by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 16: World 7-Year Perspective for Outsourced by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
    • TABLE 17: World Current & Future Analysis for Academic Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 18: World 7-Year Perspective for Academic Research by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
    • TABLE 19: World Current & Future Analysis for Clinical Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 20: World 7-Year Perspective for Clinical Research by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
    • TABLE 21: World Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 22: World 7-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
    • TABLE 23: World Current & Future Analysis for Pharma & Biotech Entities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 24: World 7-Year Perspective for Pharma & Biotech Entities by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
    • TABLE 25: World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 26: World 7-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 27: USA Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 28: USA 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2021 & 2027
    • TABLE 29: USA Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 30: USA 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2021 & 2027
    • TABLE 31: USA Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 32: USA 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2021 & 2027
    • TABLE 33: USA Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 34: USA 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities and Other End-Uses for the Years 2021 & 2027
  • CANADA
    • TABLE 35: Canada Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 36: Canada 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2021 & 2027
    • TABLE 37: Canada Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Canada 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2021 & 2027
    • TABLE 39: Canada Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 40: Canada 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2021 & 2027
    • TABLE 41: Canada Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 42: Canada 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities and Other End-Uses for the Years 2021 & 2027
  • JAPAN
    • TABLE 43: Japan Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Japan 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2021 & 2027
    • TABLE 45: Japan Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 46: Japan 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2021 & 2027
    • TABLE 47: Japan Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 48: Japan 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2021 & 2027
    • TABLE 49: Japan Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Japan 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities and Other End-Uses for the Years 2021 & 2027
  • CHINA
    • TABLE 51: China Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 52: China 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2021 & 2027
    • TABLE 53: China Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 54: China 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2021 & 2027
    • TABLE 55: China Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: China 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2021 & 2027
    • TABLE 57: China Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 58: China 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities and Other End-Uses for the Years 2021 & 2027
  • EUROPE
    • TABLE 59: Europe Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 60: Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2021 & 2027
    • TABLE 61: Europe Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2021 & 2027
    • TABLE 63: Europe Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 64: Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2021 & 2027
    • TABLE 65: Europe Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 66: Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2021 & 2027
    • TABLE 67: Europe Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities and Other End-Uses for the Years 2021 & 2027
  • FRANCE
    • TABLE 69: France Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 70: France 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2021 & 2027
    • TABLE 71: France Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 72: France 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2021 & 2027
    • TABLE 73: France Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 74: France 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2021 & 2027
    • TABLE 75: France Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 76: France 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities and Other End-Uses for the Years 2021 & 2027
  • GERMANY
    • TABLE 77: Germany Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 78: Germany 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2021 & 2027
    • TABLE 79: Germany Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Germany 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2021 & 2027
    • TABLE 81: Germany Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 82: Germany 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2021 & 2027
    • TABLE 83: Germany Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 84: Germany 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities and Other End-Uses for the Years 2021 & 2027
  • ITALY
    • TABLE 85: Italy Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Italy 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2021 & 2027
    • TABLE 87: Italy Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 88: Italy 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2021 & 2027
    • TABLE 89: Italy Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 90: Italy 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2021 & 2027
    • TABLE 91: Italy Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Italy 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities and Other End-Uses for the Years 2021 & 2027
  • UNITED KINGDOM
    • TABLE 93: UK Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 94: UK 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2021 & 2027
    • TABLE 95: UK Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 96: UK 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2021 & 2027
    • TABLE 97: UK Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 98: UK 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2021 & 2027
    • TABLE 99: UK Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 100: UK 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities and Other End-Uses for the Years 2021 & 2027
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 102: Rest of Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2021 & 2027
    • TABLE 103: Rest of Europe Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Rest of Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2021 & 2027
    • TABLE 105: Rest of Europe Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 106: Rest of Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2021 & 2027
    • TABLE 107: Rest of Europe Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 108: Rest of Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities and Other End-Uses for the Years 2021 & 2027
  • ASIA-PACIFIC
    • TABLE 109: Asia-Pacific Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Asia-Pacific 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2021 & 2027
    • TABLE 111: Asia-Pacific Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 112: Asia-Pacific 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2021 & 2027
    • TABLE 113: Asia-Pacific Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 114: Asia-Pacific 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2021 & 2027
    • TABLE 115: Asia-Pacific Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 116: Asia-Pacific 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities and Other End-Uses for the Years 2021 & 2027
  • REST OF WORLD
    • TABLE 117: Rest of World Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 118: Rest of World 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2021 & 2027
    • TABLE 119: Rest of World Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 120: Rest of World 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2021 & 2027
    • TABLE 121: Rest of World Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 122: Rest of World 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2021 & 2027
    • TABLE 123: Rest of World Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 124: Rest of World 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities and Other End-Uses for the Years 2021 & 2027

IV. COMPETITION

  • Total Companies Profiled: 111